BebtelovimabAnaphylaxis following off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1954卷 / 1期

关键词：

D O I：

10.1007/s40278-023-37931-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：113 / 113

相关论文

共 50 条

[1] SarilumabNeutropenia following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1921 (1) : 255 - 255
[2] BevacizumabEndophthalmitis following off-label use: 2 case reports
[J]. Reactions Weekly, 2019, 1757 (1) : 64 - 64
[3] FerumoxytolNausea following off-label use: 2 case reports
[J]. Reactions Weekly, 2017, 1650 (1) : 142 - 142
[4] UstekinumabMyositis following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1870 (1) : 306 - 306
[5] ClozapineAgranulocytosis following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1924 (1) : 164 - 164
[6] OctreotideCholelithiasis and vomiting following off-label use: 2 case reports
[J]. Reactions Weekly, 2020, 1810 (1) : 167 - 167
[7] TriamcinoloneOcular hypertension following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1917 (1) : 567 - 567
[8] VenetoclaxDevelopment of resistance following off-label use: 2 case reports
[J]. Reactions Weekly, 2022, 1899 (1) : 375 - 375
[9] OctreotideLack of efficacy following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1859 (1) : 288 - 288
[10] TocilizumabBowel perforation following off-label use: 2 case reports
[J]. Reactions Weekly, 2021, 1862 (1) : 459 - 459

← 1 2 3 4 5 →